AU2014385320B2 - E1E2 HCV vaccines and methods of use - Google Patents

E1E2 HCV vaccines and methods of use Download PDF

Info

Publication number
AU2014385320B2
AU2014385320B2 AU2014385320A AU2014385320A AU2014385320B2 AU 2014385320 B2 AU2014385320 B2 AU 2014385320B2 AU 2014385320 A AU2014385320 A AU 2014385320A AU 2014385320 A AU2014385320 A AU 2014385320A AU 2014385320 B2 AU2014385320 B2 AU 2014385320B2
Authority
AU
Australia
Prior art keywords
polypeptide
hcv
genotype
hcv genotype
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014385320A
Other languages
English (en)
Other versions
AU2014385320A1 (en
Inventor
Darren HOCKMAN
Michael Houghton
John L. Law
Michael Logan
D. Lorne Tyrrell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Alberta
Original Assignee
University of Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Alberta filed Critical University of Alberta
Publication of AU2014385320A1 publication Critical patent/AU2014385320A1/en
Application granted granted Critical
Publication of AU2014385320B2 publication Critical patent/AU2014385320B2/en
Priority to AU2020200216A priority Critical patent/AU2020200216A1/en
Priority to AU2022200747A priority patent/AU2022200747A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2014385320A 2013-05-15 2014-05-15 E1E2 HCV vaccines and methods of use Active AU2014385320B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2020200216A AU2020200216A1 (en) 2013-05-15 2020-01-10 E1E2 HCV vaccines and methods of use
AU2022200747A AU2022200747A1 (en) 2013-05-15 2022-02-04 E1E2 HCV vaccines and methods of use

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361823712P 2013-05-15 2013-05-15
US61/823,712 2013-05-15
US201361887229P 2013-10-04 2013-10-04
US61/887,229 2013-10-04
PCT/IB2014/001972 WO2015132619A1 (en) 2013-05-15 2014-05-15 E1e2 hcv vaccines and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020200216A Division AU2020200216A1 (en) 2013-05-15 2020-01-10 E1E2 HCV vaccines and methods of use

Publications (2)

Publication Number Publication Date
AU2014385320A1 AU2014385320A1 (en) 2015-11-12
AU2014385320B2 true AU2014385320B2 (en) 2019-10-10

Family

ID=54054625

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2014385320A Active AU2014385320B2 (en) 2013-05-15 2014-05-15 E1E2 HCV vaccines and methods of use
AU2020200216A Abandoned AU2020200216A1 (en) 2013-05-15 2020-01-10 E1E2 HCV vaccines and methods of use
AU2022200747A Abandoned AU2022200747A1 (en) 2013-05-15 2022-02-04 E1E2 HCV vaccines and methods of use

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2020200216A Abandoned AU2020200216A1 (en) 2013-05-15 2020-01-10 E1E2 HCV vaccines and methods of use
AU2022200747A Abandoned AU2022200747A1 (en) 2013-05-15 2022-02-04 E1E2 HCV vaccines and methods of use

Country Status (8)

Country Link
US (3) US20210145963A9 (enExample)
EP (2) EP2996718B1 (enExample)
JP (5) JP2016520077A (enExample)
CN (2) CN112999344A (enExample)
AU (3) AU2014385320B2 (enExample)
CA (1) CA2909586C (enExample)
CL (1) CL2015003333A1 (enExample)
WO (1) WO2015132619A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117229414A (zh) * 2015-10-08 2023-12-15 艾伯塔大学理事会 丙型肝炎病毒e1/e2异二聚体及其生产方法
AU2017332854B2 (en) 2016-09-21 2024-11-14 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof
AU2017341735B2 (en) 2016-10-11 2022-01-13 Helmholtz Center for Infection Research Hepatitis C virus immunogenic compositions comprising as an adjuvant a cyclic dinucleotide or an archaeosome and methods of use thereof
CN112601548A (zh) * 2018-03-16 2021-04-02 艾伯塔大学理事会 丙型肝炎病毒肽组合物及其使用方法
WO2025222304A1 (en) * 2024-04-26 2025-10-30 The Governors Of The University Of Alberta Hcv genotype3 e2 envelope protein for neutralizing infectivity of hcv strains

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007041432A2 (en) * 2005-09-30 2007-04-12 Novartis Vaccines And Diagnostics, Inc. Cross-neutralization of hcv with recombinant proteins
WO2009061739A1 (en) * 2007-11-06 2009-05-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralization of hcv
WO2014060851A2 (en) * 2012-10-05 2014-04-24 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
KR100310510B1 (ko) 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AU3241095A (en) 1994-07-29 1996-03-04 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
WO1998016247A1 (en) 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE69841015D1 (de) 1997-05-06 2009-09-10 Novartis Vaccines & Diagnostic Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
WO1998055609A1 (en) 1997-06-06 1998-12-10 The Regents Of The University Of California Inhibitors of dna immunostimulatory sequence activity
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
BR9909915A (pt) 1998-04-09 2000-12-26 Smithkline Beecham Biolog Composições adjuvantes
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
ES2284287T3 (es) 1998-10-16 2007-11-01 Glaxosmithkline Biologicals S.A. Sistemas adyuvantes y vacunas.
CA2366152A1 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Streptococcus pneumoniae vaccine
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
HK1049106A1 (zh) 1999-09-24 2003-05-02 Smithkline Beecham Biologicals S.A. 聚氧化乙烯山梨糖酯和octooxynol的聯用做為佐劑和其在疫苗中的用途
IL148671A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
AU2002322358B2 (en) * 2001-06-29 2009-06-18 Novartis Vaccines And Diagnostics, Inc. HCV E1E2 vaccine compositions
US7348011B2 (en) * 2005-06-10 2008-03-25 Sudershan Biotech Ltd. Hepatitis C virus vaccine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007041432A2 (en) * 2005-09-30 2007-04-12 Novartis Vaccines And Diagnostics, Inc. Cross-neutralization of hcv with recombinant proteins
WO2009061739A1 (en) * 2007-11-06 2009-05-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralization of hcv
WO2014060851A2 (en) * 2012-10-05 2014-04-24 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GROLLO LARA ET AL, ANTIVIRAL THERAPY- AN OFFICIAL PUBLICATION OF THE INTERNATIONAL SOCIETY FOR ANTIVIRAL RESEARCH, MTM PUBLICATIONS, LONDON, GB, (2006-01-01), vol. 11, no. 8, ISSN 1359-6535, pages 1005 - 1014 *

Also Published As

Publication number Publication date
HK1216395A1 (en) 2016-11-11
EP2996718B1 (en) 2020-01-15
WO2015132619A1 (en) 2015-09-11
AU2020200216A1 (en) 2020-02-06
CN112999344A (zh) 2021-06-22
US20210145963A9 (en) 2021-05-20
CN105263517A (zh) 2016-01-20
CL2015003333A1 (es) 2016-09-30
US20230098265A1 (en) 2023-03-30
AU2014385320A1 (en) 2015-11-12
JP2016520077A (ja) 2016-07-11
US20240316186A1 (en) 2024-09-26
CN105263517B (zh) 2021-03-26
JP2019142962A (ja) 2019-08-29
US20160067332A1 (en) 2016-03-10
JP2021059596A (ja) 2021-04-15
EP2996718A4 (en) 2017-06-21
AU2022200747A1 (en) 2022-02-24
CA2909586A1 (en) 2015-09-11
CA2909586C (en) 2021-08-31
JP2024156917A (ja) 2024-11-06
JP2022172244A (ja) 2022-11-15
EP2996718A1 (en) 2016-03-23
EP3689375A1 (en) 2020-08-05

Similar Documents

Publication Publication Date Title
US20240316186A1 (en) E1e2 hcv vaccines and methods of use
US12202859B2 (en) Hepatitis c virus E1/E2 heterodimers and methods of producing same
US20230310590A1 (en) Hepatitis c virus immunogenic compositions and methods of use thereof
AU2017332854B2 (en) Hepatitis C virus immunogenic compositions and methods of use thereof
WO2014060851A2 (en) Hepatitis c virus immunogenic compositions and methods of use thereof
HK1216395B (en) E1e2 hcv vaccines and methods of use
HK40120034A (en) Hepatitis c virus e1/e2 heterodimers and methods of producing same
HK1255379B (en) Hepatitis c virus immunogenic compositions and methods of use thereof

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ HOUGHTON, MICHAEL; HOCKMAN, DARREN; LAW, JOHN L.; LOGAN, MICHAEL AND TYRRELL, D. LORNE

FGA Letters patent sealed or granted (standard patent)